MedWatch

GN Hearing's top line took a dive in Q1 – firm maintains 2021 guidance

Hearing aid manufacturer GN Hearing expects to grow more than 25 percent organically in 2021. In the first quarter, organic growth was 1 percent, according to interim report on Thursday.

Photo: GN Store Nord / PR

GN Hearing's interim report, published on Thursday, hardly holds any surprises. Three weeks ago, GN hearing had already unveiled a list of figures for the first three months of the year in connection with upgrading its other business leg GN Audio.

As implied then, the interim report on Thursday states that GN Hearing will maintain its guidance for the rest of 2021.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs